share_log
Reuters ·  Mar 26 11:30
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Transthyretin (Attr) Amyloidosis With Cardiomyopathy
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 351

Recommended

Write a comment